Digital Tomosynthesis Effectively Estimates Structural Lung Disease in Cystic Fibrosis
Digital tomosynthesis of the chest offers effective quantitative estimation of structural lung disease in patients with cystic fibrosis.
Obstructive Lung Disease
Mannitol Inhalation Powder Now Available as Add-On Maintenance Therapy for Cystic Fibrosis
Bronchitol should only be used by adults who have passed the Bronchitol Tolerance Test.
Telehealth for Cystic Fibrosis During COVID-19 Largely Accepted by Clinicians
Clinicians across multiple disciplines largely accepted telehealth in the cystic fibrosis care model during the COVID-19 pandemic.
Elexacaftor-Tezacaftor-Ivacaftor Associated With Rapid Improvement in Cystic Fibrosis
In patients with cystic fibrosis with advanced lung disease, initiation of elexacaftor-tezacaftor-ivacaftor is associated with rapid clinical improvement and a decreased need for lung transplantation.
Hormonal Contraception May Have Beneficial Effects for Women With Cystic Fibrosis
Women with cystic fibrosis have inflammatory biomarker fluctuations in the lungs that correlate with changes in lung function, opening the possibility of sex hormone linked changes.
FDA Expands Use of Multiple Cystic Fibrosis Medications
The full list of CFTR gene mutations for Trikafta, Symdeko and Kalydeco can be found in the updated prescribing information for each respective product.
Vitamin D Deficiency is Associated With NTM in Cystic Fibrosis
Vitamin D deficiency is associated with a higher risk of incident nontuberculous mycobacteria respiratory isolation in adults with cystic fibrosis.
Mannitol Approved as Add-On Maintenance Therapy for Cystic Fibrosis
Bronchitol is only indicated for use in adults who have passed the Bronchitol Tolerance Test.
Ivacaftor May Be Effective for Infants With Cystic Fibrosis and Gating Mutation
Ivacaftor was safe and associated with improvements in cystic fibrosis transmembrane conductance regulator function in infants with CF and a gating mutation.
Increased GERD Risk in End-Stage Lung Disease Without Esophageal Disease
End-stage lung disease may significantly increase the risk for gastroesophageal reflux disease (GERD) in patients undergoing lung transplant without primary esophageal disease.
- Loading...
Loading...
Next post in CHEST 2020
Loading... 
Loading...